STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
Status:
Completed
Trial end date:
2017-06-14
Target enrollment:
Participant gender:
Summary
This single-arm, open-label, multi-center study will evaluate the safety and efficacy of
vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma.
Patients will receive oral doses of vismodegib 150 mg once daily until disease progression or
unacceptable toxicity.